Roberto Mina

2.9k total citations
51 papers, 679 citations indexed

About

Roberto Mina is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Roberto Mina has authored 51 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Hematology, 31 papers in Oncology and 29 papers in Molecular Biology. Recurrent topics in Roberto Mina's work include Multiple Myeloma Research and Treatments (49 papers), Protein Degradation and Inhibitors (23 papers) and Peptidase Inhibition and Analysis (20 papers). Roberto Mina is often cited by papers focused on Multiple Myeloma Research and Treatments (49 papers), Protein Degradation and Inhibitors (23 papers) and Peptidase Inhibition and Analysis (20 papers). Roberto Mina collaborates with scholars based in Italy, United States and Netherlands. Roberto Mina's co-authors include Antonio Palumbo, Francesca Gay, Mario Boccadoro, Sara Bringhen, Sagar Lonial, Alessandra Larocca, Francesca Bonello, Chiara Cerrato, Mattia D’Agostino and Charise Gleason and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Roberto Mina

48 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Roberto Mina Italy 15 564 483 380 84 37 51 679
Jose Estevam United States 11 627 1.1× 566 1.2× 361 0.9× 82 1.0× 45 1.2× 16 754
Ying-Ming Jou United States 6 349 0.6× 353 0.7× 439 1.2× 77 0.9× 60 1.6× 8 631
Nisha S. Joseph United States 13 645 1.1× 498 1.0× 389 1.0× 107 1.3× 68 1.8× 69 783
Luis Palomera Spain 10 596 1.1× 465 1.0× 345 0.9× 115 1.4× 50 1.4× 25 671
Valeria Magarotto Italy 12 565 1.0× 669 1.4× 345 0.9× 61 0.7× 47 1.3× 32 837
Loredana Santo United States 9 456 0.8× 383 0.8× 326 0.9× 59 0.7× 83 2.2× 23 633
Annemiek Broijl Netherlands 13 545 1.0× 463 1.0× 403 1.1× 70 0.8× 106 2.9× 50 710
Jeana Cromer United States 6 802 1.4× 557 1.2× 413 1.1× 64 0.8× 63 1.7× 6 870
Daniele Derudas Italy 9 494 0.9× 369 0.8× 258 0.7× 127 1.5× 51 1.4× 30 624
PR Greipp United States 11 577 1.0× 414 0.9× 289 0.8× 114 1.4× 38 1.0× 12 635

Countries citing papers authored by Roberto Mina

Since Specialization
Citations

This map shows the geographic impact of Roberto Mina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto Mina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto Mina more than expected).

Fields of papers citing papers by Roberto Mina

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto Mina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto Mina. The network helps show where Roberto Mina may publish in the future.

Co-authorship network of co-authors of Roberto Mina

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto Mina. A scholar is included among the top collaborators of Roberto Mina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto Mina. Roberto Mina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
D’Agostino, Mattia, Marina Martello, Lorenzo De Paoli, et al.. (2025). Overview of 1q abnormalities in multiple myeloma: scientific opinions from Italian experts. Annals of Hematology. 104(3). 1443–1458. 1 indexed citations
2.
Landgren, Ola, Noa Biran, Elizabeth O’Donnell, et al.. (2025). Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma. HemaSphere. 9(7). e70178–e70178.
3.
Mella, Alberto, Valeria Deiana, Ester Gallo, et al.. (2025). Pre-existing oncohematological disease in kidney transplant recipients: impact on graft survival, acute rejection, and long-term clinical outcomes. Frontiers in Immunology. 16. 1629521–1629521. 1 indexed citations
4.
Rodríguez‐Otero, Paula, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2024). Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.. Journal of Clinical Oncology. 42(16_suppl). 7502–7502. 9 indexed citations
5.
6.
Bonello, Francesca, Serena Rocchi, Gregorio Barilà, et al.. (2022). Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma. Frontiers in Oncology. 12. 851864–851864. 11 indexed citations
7.
Mina, Roberto & Francesca Gay. (2021). The role of autologous stem-cell transplantation in multiple myeloma in 2021. Current Opinion in Oncology. 33(6). 642–647. 3 indexed citations
8.
Oliva, Stefania, Lorenzo De Paoli, Marina Ruggeri, et al.. (2021). A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma. Annals of Hematology. 100(2). 437–443. 8 indexed citations
9.
Mina, Roberto & Francesca Gay. (2021). Antibody-drug conjugates: when chemotherapy meets immuno-oncology. The Lancet Haematology. 8(11). e778–e779. 1 indexed citations
10.
Mina, Roberto, Francesca Bonello, & Stefania Oliva. (2021). Minimal Residual Disease in Multiple Myeloma. The Cancer Journal. 27(3). 247–255. 6 indexed citations
11.
Mina, Roberto, Stefania Oliva, & Mario Boccadoro. (2020). Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. Journal of Clinical Medicine. 9(7). 2142–2142. 13 indexed citations
12.
Kaufman, Jonathan L., Roberto Mina, Jatin J. Shah, et al.. (2020). Phase 1 Trial Evaluating Vorinostat Plus Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 20(12). 797–803. 5 indexed citations
13.
Mina, Roberto, Francesca Bonello, Francesca Gay, Elena Zamagni, & Mario Boccadoro. (2020). Daratumumab-Based Therapy for IgM Multiple Myeloma With Hyperviscosity Syndrome: A Case Report. Clinical Lymphoma Myeloma & Leukemia. 21(1). e21–e24. 2 indexed citations
14.
Bonello, Francesca, Roberto Mina, Mario Boccadoro, & Francesca Gay. (2019). Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma. Cancers. 12(1). 15–15. 38 indexed citations
15.
Mina, Roberto & Sagar Lonial. (2019). Is there still a role for stem cell transplantation in multiple myeloma?. Cancer. 125(15). 2534–2543. 20 indexed citations
16.
Bringhen, Sara, Roberto Mina, Maria Teresa Petrucci, et al.. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica. 104(8). 1640–1647. 19 indexed citations
17.
Mina, Roberto, Nisha S. Joseph, Jonathan L. Kaufman, et al.. (2018). Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer. 125(3). 416–423. 34 indexed citations
18.
Bringhen, Sara, Roberto Mina, Anna Maria Cafro, et al.. (2018). Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia. 32(8). 1803–1807. 34 indexed citations
19.
Larocca, Alessandra, Vittorio Montefusco, Sara Bringhen, et al.. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. Blood. 122(16). 2799–2806. 66 indexed citations
20.
Palumbo, Antonio & Roberto Mina. (2013). Management of older adults with multiple myeloma. Blood Reviews. 27(3). 133–142. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jose Estevam Breakdown of academic impact, for papers by Ying-Ming Jou Breakdown of academic impact, for papers by Nisha S. Joseph Breakdown of academic impact, for papers by Luis Palomera Breakdown of academic impact, for papers by Valeria Magarotto Breakdown of academic impact, for papers by Loredana Santo Breakdown of academic impact, for papers by Annemiek Broijl Breakdown of academic impact, for papers by Jeana Cromer Breakdown of academic impact, for papers by Daniele Derudas Breakdown of academic impact, for papers by PR Greipp
Rankless by CCL
2026